How does medroxyprogesterone acetate (Provera) work for abnormal uterine bleeding secondary to multiple uterine fibroids?

How Provera Works for Abnormal Uterine Bleeding Secondary to Multiple Fibroids

Provera (medroxyprogesterone acetate) stabilizes the endometrium and reduces bleeding in fibroid-related abnormal uterine bleeding by counteracting unopposed estrogen effects, though it is FDA-approved specifically for abnormal uterine bleeding "due to hormonal imbalance in the absence of organic pathology, such as fibroids" 1.

Mechanism of Action in Fibroid-Related Bleeding

Despite the FDA label's cautionary language, Provera works through several mechanisms when fibroids cause abnormal bleeding:

• Endometrial stabilization: Progestins transform proliferative endometrium into secretory endometrium, reducing the fragility and irregular shedding that causes heavy bleeding
• Vascular effects: Decreases endometrial blood flow and promotes hemostasis at the molecular level
• Hormonal counterbalance: Opposes estrogen-driven endometrial proliferation that fibroids can exacerbate

Clinical Evidence and Positioning

The evidence base is limited but shows benefit:

Depot formulation (DMPA 150mg IM) demonstrated in a pilot study that 70% of women with symptomatic fibroids had improved bleeding patterns, 30% achieved amenorrhea, and fibroid volume decreased by 33% over 6 months 2. This represents the strongest direct evidence for medroxyprogesterone in fibroid-related bleeding.

Oral medroxyprogesterone is positioned as second-line therapy per current guidelines 3. First-line medical management includes NSAIDs, combined oral contraceptives, and tranexamic acid. The 2024 ACR guidelines place progestins after these options but before GnRH agonists/antagonists.

Dosing Protocols

Per FDA labeling 1:

• 5-10 mg daily for 5-10 days for abnormal uterine bleeding
• Bleeding typically stops within 3-7 days of initiating therapy
• May be cycled monthly (e.g., days 16-25 of cycle) for ongoing management

For acute bleeding, combination protocols show higher efficacy: DMPA 150mg IM plus oral medroxyprogesterone 20mg every 8 hours for 3 days stopped bleeding in 100% of women within 5 days (mean 2.6 days) 4.

Critical Limitations and Caveats

The FDA label explicitly states Provera is indicated for abnormal bleeding "in the absence of organic pathology, such as fibroids" 1. This creates a clinical paradox—it's commonly used off-label for fibroid bleeding despite this language.

Why this matters clinically:

• Structural lesions (fibroids, polyps, adenomyosis) should be identified before attributing bleeding solely to hormonal causes
• Submucosal fibroids distorting the endometrial cavity respond poorly to medical management alone
• Large or multiple fibroids may require definitive surgical management

Comparative effectiveness: The levonorgestrel-releasing IUS shows superior efficacy for fibroid-related bleeding compared to oral progestins, though evidence quality is very low 5. A 2026 study confirmed LNG-IUS achieved 93% reduction in bleeding scores at 6 months versus lower reductions with oral progestins 6.

When Provera Is Appropriate

Use oral medroxyprogesterone when:

• Fibroids are small-to-moderate sized without significant cavity distortion
• Patient declines or cannot tolerate LNG-IUS
• Acute bleeding control is needed as a bridge to definitive therapy
• Patient is perimenopausal and approaching natural fibroid regression

Avoid as monotherapy when:

• Submucosal fibroids >3cm are present (hysteroscopic resection preferred)
• Severe anemia exists (hemoglobin <7 g/dL)—address surgically
• Bleeding persists after 3 months of adequate therapy
• Uterine size exceeds 12-week gestational equivalent

Practical Algorithm

1. Confirm fibroid diagnosis with transvaginal ultrasound; assess size, number, and location
2. Check hemoglobin and iron studies
3. For intramural/subserosal fibroids with heavy bleeding:
   • Start medroxyprogesterone 10mg daily for 10 days
   • Reassess at 3 months; if improved, cycle monthly
   • If inadequate response, escalate to LNG-IUS or GnRH therapy
4. For submucosal fibroids: Refer for hysteroscopic evaluation/resection rather than relying on medical management
5. For acute heavy bleeding: Consider DMPA 150mg IM + oral MPA 20mg TID × 3 days 4

The 2024 ACR guidelines emphasize that perimenopausal women may benefit most from temporizing medical therapy since fibroids naturally regress after menopause 3. This makes Provera particularly useful as a bridge in women within 2-3 years of expected menopause.